InvestorsHub Logo
Followers 122
Posts 17458
Boards Moderated 0
Alias Born 01/06/2014

Re: None

Sunday, 02/13/2022 5:01:31 PM

Sunday, February 13, 2022 5:01:31 PM

Post# of 425931
Are we, as shareholders not owed an explanation from Amarin regarding Amarin:

• not pursuing the Curfman/Bhatt paper
• not identifying statistical errors during the trial
• not using their in-house (S)hero biostatistician
• not assisting Marjac with rule 24/60

I understand Amarin's policy of not commenting on ongoing legal matters, but this is no longer "ongoing" from their end. Their case ended when the Supreme Court refused to accept their Writ of Certiorari and since they don't help Marjac, there isn't anything "ongoing".

How about we send them 100+ emails, demanding answers to our unanswered questions?

IMO they won't comment because of utter embarrassment of how they handled it and the fear of whatever they say, being used against them in a future class action lawsuit by shareholders.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News